Your browser doesn't support javascript.
loading
Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary.
Lu, Wenying; Aarsand, Rebekka; Schotte, Kerstin; Han, Jing; Lebedeva, Elizaveta; Tsoy, Elena; Maglakelidze, Nino; Soriano, Joan B; Bill, Werner; Halpin, David M G; Rivera, M Patricia; Fong, Kwun M; Kathuria, Hasmeena; Yorgancioglu, Arzu; Gappa, Monika; Lam, David Cl; Rylance, Sarah; Sohal, Sukhwinder Singh.
Afiliación
  • Lu W; Respiratory Translational Research Group, Department of Laboratory Medicine, School of Health Sciences, College of Health and Medicine, University of Tasmania, Locked Bag - 1322, Newnham Drive, Launceston, TAS, 7248, Australia.
  • Aarsand R; Department of Digital Health and Innovation, World Health Organization, Geneva, Switzerland.
  • Schotte K; Department of Health Promotion, World Health Organization, Geneva, Switzerland.
  • Han J; Department of Digital Health and Innovation, World Health Organization, Geneva, Switzerland.
  • Lebedeva E; Tobacco Control Unit, Special Initiative on NCDs and Innovation, World Health Organization Regional Office for Europe, Copenhagen, Denmark.
  • Tsoy E; Noncommunicable Diseases Management Unit, Special Initiative on NCDs and Innovation, World Health Organization Regional Office for Europe, Copenhagen, Denmark.
  • Maglakelidze N; WHO European Regional Office, Strategic Development Adviser - Tbilisi State Medical Academy, Paris, France.
  • Soriano JB; Noncommunicable Diseases Management Unit, Special Initiative on NCDs and Innovation, World Health Organization Regional Office for Europe, Copenhagen, Denmark.
  • Bill W; Servicio de Neumología, Hospital Universitario de la Princesa, Facultad de Medicina, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Universidad Autónoma de Madrid, Instituto de Salud Carlos III, Madrid, Spain.
  • Halpin DMG; European Respiratory Society, Lausanne, Switzerland.
  • Rivera MP; University of Exeter College of Medicine, University of Exeter Medical School, Exeter, UK.
  • Fong KM; Royal Devon and Exeter Hospital, Exeter, UK.
  • Kathuria H; Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Rochester, New York, USA.
  • Yorgancioglu A; Department of Thoracic Medicine, The Prince Charles Hospital, University of Queensland Thoracic Research Centre, Brisbane, Australia.
  • Gappa M; Center for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
  • Lam DC; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
  • Rylance S; Department of Pulmonology, Celal Bayar University Medical Faculty, Manisa, Turkey.
  • Sohal SS; Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany.
Respir Res ; 25(1): 338, 2024 Sep 11.
Article en En | MEDLINE | ID: mdl-39261873
ABSTRACT
The WHO recently published a Tobacco Knowledge Summary (TKS) synthesizing current evidence on tobacco and COPD, aiming to raise awareness among a broad audience of health care professionals. Furthermore, it can be used as an advocacy tool in the fight for tobacco control and prevention of tobacco-related disease. This article builds on the evidence presented in the TKS, with a greater level of detail intended for a lung-specialist audience. Pulmonologists have a vital role to play in advocating for the health of their patients and the wider population by sharing five key messages (1) Smoking is the leading cause of COPD in high-income countries, contributing to approximately 70% of cases. Quitting tobacco is an essential step toward better lung health. (2) People with COPD face a significantly higher risk of developing lung cancer. Smoking cessation is a powerful measure to reduce cancer risk. (3) Cardiovascular disease, lung cancer and type-2 diabetes are common comorbidities in people with COPD. Quitting smoking not only improves COPD management, but also reduces the risk of developing these coexisting conditions. (4) Tobacco smoke also significantly impacts children's lung growth and development, increasing the risk of respiratory infections, asthma and up to ten other conditions, and COPD later in life. Governments should implement effective tobacco control measures to protect vulnerable populations. (5) The tobacco industry's aggressive strategies in the marketing of nicotine delivery systems and all tobacco products specifically target children, adolescents, and young adults. Protecting our youth from these harmful tactics is a top priority.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Organización Mundial de la Salud / Enfermedad Pulmonar Obstructiva Crónica Límite: Humans Idioma: En Revista: Respir Res Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Organización Mundial de la Salud / Enfermedad Pulmonar Obstructiva Crónica Límite: Humans Idioma: En Revista: Respir Res Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido